Alterations predicting sensitivity to PI3K/AKT/mTOR, CDK and HER2/EGFR inhibitors were identified and, importantly, in 53% of patients, these clinically informative or targetable mutations were not detected in the primary tumours. The gene discussed is ERBB2; the disease is neoplasm.